With 12.74 million shares changed hands, the volume of the stock remained heavier than its average volume of 58230.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.99 whereas the lowest price it dropped to was $1.8301. The 52-week range on VIVS shows that it touched its highest point at $21.96 and its lowest point at $1.41 during that stretch. It currently has a 1-year price target of $64.80. Beta for the stock currently stands at 1.10.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VIVS was up-trending over the past week, with a rise of 15.64%, but this was up by 30.48% over a month. Three-month performance surged to 35.56% while six-month performance fell -68.72%. The stock lost -55.79% in the past year, while it has lost -67.10% so far this year.
Float and Shares Shorts:
At present, 2.60 million VIVS shares are outstanding with a float of 2.57 million shares on hand for trading. On 2025-08-15, short shares totaled 43477.0, which was 167.0 higher than short shares on 1752537600. In addition to Mr. Keith E. Murphy as the firm’s Executive Chairman & Corporate Secretary, Mr. Norman Staskey serves as its President, CFO & Principal Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, VIVS reported revenue of $37000.0 and operating income of -$2915000.0. The EBITDA in the recently reported quarter was -$2778000.0 and diluted EPS was -$1.14.
